CLASS III Drug recall · Reported 17 Jul 2013 · FDA Enforcement Report

Balziva(TM) (norethindrone and ethinyl estradiol tablets recalled

Teva Pharmaceuticals USA is recalling Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 15 mg/0.03 mg, 28 day, distributed nationwide in the US. The recall was initiated on 15 Mar 2013 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesNDC 0555-9034-58, Lot numbers 33802100A, exp 3/2013; 33802266A, exp 3/2013; and 33802832A, exp 8/2013.
NDC0555-9034
Quantity recalled36,708 blister packs

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-684-2013
FDA event ID
64644
Recalling firm
Teva Pharmaceuticals USA, Sellersville, PA
Brand
Balziva
Manufacturer
Teva Pharmaceuticals USA, Inc.
Classification
Class III
Status
Terminated
Recall initiated
15 Mar 2013
FDA classified
5 Jul 2013
Reported
17 Jul 2013
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Benzene

Timeline

15 Mar 2013Recall initiated by company
5 Jul 2013Classified by FDA+112 days
17 Jul 2013Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Product as listed by the FDA

Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58

Where it was distributed

Nationwide distribution. No foreign or government accounts.

Nationwide

Questions about this recall

Is Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 15 mg/0.03 mg, 28 day recalled?

Yes. Teva Pharmaceuticals USA recalled Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 15 mg/0.03 mg, 28 day on 15 Mar 2013. The recall is Class III and its status is Terminated. Recall number D-684-2013.

Why was it recalled?

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Which lots are affected?

NDC 0555-9034-58, Lot numbers 33802100A, exp 3/2013; 33802266A, exp 3/2013; and 33802832A, exp 8/2013.

Where was it sold?

Nationwide distribution. No foreign or government accounts.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Teva Pharmaceuticals USA

All 84

Other Norethindrone recalls

All 5